African Platform Eyes $750m Investment
Deal Sees Egypt’s Adwia Pharmaceuticals Combined With India’s Celon Laboratories
Executive Summary
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.
You may also be interested in...
Innovent Expands Internationally With Indonesia Deal
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
FDA Guides On Bioequivalence Studies And COVID-19
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.
Teva Takes On Amneal With Second US NuvaRing Rival
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: